The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.
 
Weijian Guo
No Relationships to Disclose
 
Yusheng Wang
No Relationships to Disclose
 
Wenhui Yang
No Relationships to Disclose
 
Yunfeng Li
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Zhongtao Zhang
No Relationships to Disclose
 
Hailin Xiong
No Relationships to Disclose
 
Changzheng Li
No Relationships to Disclose
 
Zhiwu Wang
No Relationships to Disclose
 
Nanfeng Fan
No Relationships to Disclose
 
Xianli Yin
No Relationships to Disclose
 
Peng Du
No Relationships to Disclose
 
Suxia Luo
No Relationships to Disclose
 
Jingdong Zhang
No Relationships to Disclose
 
Dajun Yu
No Relationships to Disclose
 
Weie Zheng
No Relationships to Disclose
 
Xiaoyan Kang
Employment - QiLu Pharmaceutical
 
Kaisheng Mao
Employment - QiLu Pharmaceutical
 
Zhan Wang
Employment - QiLu Pharmaceutical
 
Lin Shen
No Relationships to Disclose